Tekla Capital Management LLC Aurinia Pharmaceuticals Inc. Transaction History

Tekla Capital Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$17.78 - $33.08 $1.6 Million - $2.98 Million	-90,222 Reduced 35.69%	162,599 $3.72 Million
Q3 2021 Nov 12, 2021	SELL	$10.93 - $23.55 $1.59 Million - $3.42 Million	-145,099 Reduced 36.46%	252,821 $5.6 Million
Q1 2021 May 14, 2021	BUY	$12.3 - $18.73 $1.2 Million - $1.82 Million	97,309 Added 32.37%	397,920 $5.17 Million
Q3 2020 Nov 13, 2020	BUY	$13.19 - $16.66 $2.77 Million - $3.5 Million	209,823 Added 231.11%	300,611 $4.43 Million
Q4 2019 Feb 13, 2020	BUY	$3.88 - $21.42 $352,257 - $1.94 Million	90,788 New	90,788 $1.84 Million

227

58.9M

949K

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.14B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Tekla Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Tekla Capital Management LLC with notifications on news.